Immunic, Inc.
IMUXNASDAQHealthcare● Active
$12.06
$-0.71(-5.56%)
Market Cap$119014580
P/E Ratio—
52W High$15.77
52W Low$5.06
Immunic, Inc. (IMUX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMUX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.08B | $0.08B | $0.07B | $0.06B |
| G&A Expenses | $0.02B | $0.02B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.10B | $0.10B | $0.10B | $0.12B | $0.09B |
| Operating Income | ($0.10B) | ($0.10B) | ($0.10B) | ($0.12B) | ($0.09B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.10B) | ($0.10B) | ($0.09B) | ($0.12B) | ($0.09B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.10B) | ($0.10B) | ($0.09B) | ($0.12B) | ($0.09B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.24 | $-10.00 | $-21.10 | $-37.80 | $-39.20 |
| Wtd Avg Shares | 0.02B | 0.01B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.10B) | ($0.10B) | ($0.10B) | ($0.09B) | ($0.09B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Immunic, Inc. data
About Immunic, Inc. (IMUX) Income Statement
Immunic, Inc. (IMUX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IMUX reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.10B) — a net profit margin of —.
Frequently asked questions
IMUX · 4 questionsImmunic, Inc. (IMUX) reported revenue of $0.00B for 2025, down —% year-over-year.
IMUX revenueIMUX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09